Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
L-CarnitineSmall moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: Carnitor, L-carnitine, levocarnitine
Oral carnitine supplements deliver just 15 to 18 percent of their dose to your bloodstream. Injectable levocarnitine hits 100 percent bioavailability by skipping the gut entirely. L-Carnitine (brand name Carnitor) earned FDA approval in 1999 for primary and secondary carnitine deficiency. The clinical story is straightforward: this amino acid derivative ferries long-chain fatty acids into mitochondria for beta-oxidation. A 2020 meta-analysis of 37 RCTs (n=2,292)[1] confirmed a mean 1.21 kg weight reduction vs placebo. The fat loss is modest on its own. Stacked with a caloric deficit and training, though, it becomes a useful metabolic tool, and GLP-1 clinics have caught on.
A 37-study meta-analysis landed on 1.21 kg average weight loss vs placebo. That number looks small until you understand the context. L-Carnitine (levocarnitine, CAS 541-15-1) is the only transport system that moves long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Without it, your cells can't burn stored fat efficiently. The pharmacokinetic gap between oral and injectable is what makes this compound interesting to the wellness community. Oral supplements at 2,000 mg deliver roughly 15 to 18 percent to circulation. Above that dose, intestinal transporters saturate and absorption actually drops. Injectable levocarnitine bypasses the gut for 100 percent bioavailability. The FDA approved Carnitor injection (200 mg/mL) in 1999 for diagnosed carnitine deficiency. Compounding pharmacies now produce 500 mg/mL concentrations in 30 mL vials, making daily intramuscular dosing practical at home. The standard community protocol runs 500 mg IM daily for 8 to 12 weeks. GLP-1 clinics frequently prescribe 250 to 500 mg three times weekly alongside semaglutide or tirzepatide. A 2025 RCT (n=32)[2] found that 2,970 mg/day for 12 weeks improved peripheral insulin sensitivity in type 2 diabetes patients. Skeletal muscle acetylcarnitine rose 31 percent at rest. An umbrella meta-analysis the same year (n=16,352) confirmed a 1.34 cm waist circumference reduction. Results are more pronounced in overweight individuals and those with metabolic dysfunction. The effect is additive, not standalone; nobody loses 20 pounds from carnitine alone.
The carnitine shuttle is the only gateway for long-chain fatty acids (14+ carbons) to reach beta-oxidation machinery inside the mitochondria. Three enzymes run the system in sequence. Carnitine palmitoyltransferase I (CPT-I) sits on the outer mitochondrial membrane. It transfers the fatty acyl group from coenzyme A to L-Carnitine, forming acylcarnitine. Next, carnitine-acylcarnitine translocase (CACT) moves that acylcarnitine across the inner membrane. Simultaneously, it exports free carnitine back to the outer side. CPT-II on the matrix side cleaves the acylcarnitine apart, releasing fatty acyl-CoA for beta-oxidation and regenerating free carnitine for another round. Beyond fatty acid transport, L-Carnitine buffers the intracellular CoA pool. During metabolic stress or high-fat feeding, acyl-CoA esters pile up. Carnitine accepts those acyl groups, freeing CoA for the citric acid cycle and pyruvate oxidation. This buffering action prevents metabolic bottlenecks and maintains cellular energy flexibility. About 76 percent of an injected dose gets cleared through the kidneys within 24 hours [3]. The body regulates circulating carnitine tightly via renal reabsorption. That built-in ceiling means accumulation risk is low, but it also explains why consistent daily dosing matters more than occasional large boluses.
Modest but statistically robust weight reduction with L-carnitine supplementation (~1.21 kg vs placebo across 37 RCTs). Improved insulin sensitivity and lipid markers confirmed in T2D populations in 2024 meta-analyses. Injectable-specific body composition RCTs do not exist: the bioavailability advantage (100% injectable vs 15-18% oral) is extrapolated from PK data, not direct RCT comparison.
Ramanathan et al. 2020: meta-analysis of 37 RCTs, n=2,292 (PMID 32359762): WMD body weight -1.21 kg vs placebo. Umbrella meta-analysis 2025 (IJVNR, n=16,352): weight -1.11 kg, waist -1.34 cm. PMID 40019115 (2025 RCT, n=32 T2D): 2,970 mg/day × 12 weeks improved peripheral insulin sensitivity (ΔRd +3.3 µmol/kg/min, p=0.005) and hepatic insulin sensitivity (p=0.020).
All body composition RCTs use oral supplementation. No head-to-head RCT of injectable vs oral for body composition endpoints. Mean weight loss of ~1.2 kg is modest and may be clinically insignificant without a concurrent caloric deficit. High statistical heterogeneity across meta-analyses. No peer-reviewed RCTs specifically evaluating 500-1,000 mg/day IM dosing.
Well-regarded GLP-1 clinic adjunct and metabolic support tool. Energy improvement is the most universally reported benefit. Fat loss is viewed as additive to a caloric deficit, not a standalone effect. Injectable route strongly preferred over oral for practical reasons: smaller volume, no GI load, no TMAO production.
Science and community both conclude L-carnitine provides modest but real metabolic support: a supplemental tool, not a primary fat loss driver. Divergence: all human RCTs use oral supplementation; community exclusively uses injectable. Community also reports energy and performance benefits (reduced DOMS, pump, AR upregulation) that RCT endpoints do not specifically measure. The injectable PK advantage (100% vs 15-18% bioavailability) is physiologically sound but not formally confirmed in body composition RCTs.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250mg | Daily |
| Moderate | 500mg | Daily |
| Aggressive | 1000mg | Daily |
Pre-filled injectable solution. No reconstitution, no bacteriostatic water, no mixing math. That alone makes L-Carnitine one of the easiest injectables to work with. Two concentrations matter. Carnitor (FDA brand) comes at 200 mg/mL. Compounded versions run 500 mg/mL. Read the vial label before you draw. At 200 mg/mL, a 500 mg dose is 2.5 mL; that's a lot of fluid for one IM site. At 500 mg/mL, the same dose is just 1.0 mL (100 units on an insulin syringe). Most community users go with 500 mg/mL compounded for this reason. Don't inject subcutaneously at 500 mg/mL. The solution is hypertonic and creates nodules that can persist for months. IM only at that concentration. If SC is your only option, use 200 mg/mL. Warm the vial to room temperature before injecting. Cold solution burns more going in. Gluteal muscle handles the volume best; deltoid works if the volume is under 1.5 mL.
No strict cycling requirement for carnitine deficiency patients (continuous use approved). For body composition goals, 8-12 weeks on followed by 4 weeks off is common practice to assess baseline and avoid TMAO accumulation from any concurrent oral intake.
L-carnitine is an endogenous molecule with no receptor desensitization mechanism. Continuous use is FDA-approved for clinical deficiency with no mandated cycling. The community 8-12 week on / 4-week off cycle is a practical protocol, not a physiological requirement. Rationale: (1) baseline assessment: determining whether benefits persist without supplementation; (2) reducing cumulative TMAO exposure if concurrent oral carnitine is also being used; (3) cost management. The body tightly regulates circulating carnitine via renal reabsorption (~76% of an injected dose excreted renally within 24 hours), providing an inherent ceiling on accumulation.
Or use the universal Peptide Calculator for any peptide.
Expected: Additive fat loss support (mean ~1.21 kg at matched bioavailable oral dose per RCT data); improved energy and exercise recovery. No meaningful effect without concurrent caloric deficit.
Monitor: No mandatory labs for otherwise healthy individuals. Monitor for fishy body odor (reduce/discontinue concurrent oral carnitine). Check thyroid function at 6-8 weeks if on levothyroxine (carnitine reduces cellular thyroid hormone uptake).
Compounded L-Carnitine typically comes as 500 mg/mL in a 30 mL multi-use vial. Carnitor (FDA brand) is 200 mg/mL.
At 500 mg/mL: 250 mg = 0.5 mL (50 units on a 1 mL insulin syringe). 500 mg = 1.0 mL (100 units). 1,000 mg = 2.0 mL (use a standard 3 mL syringe). At 200 mg/mL: 500 mg = 2.5 mL. 1,000 mg = 5.0 mL (split across two sites or use a larger syringe).
Run it under warm water for 60 seconds or hold it in your hand for 2 to 3 minutes. Cold solution causes more burning on injection.
Switch to an injection needle: 23-25g, 1 to 1.5 inch for intramuscular depth.
Injection sites: gluteal muscle (upper outer quadrant) handles larger volumes best. Deltoid works for doses under 1.5 mL. Inject slowly over 30 to 60 seconds.
With a 17-hour half-life, single daily dosing maintains adequate levels regardless of exact timing.
Multi-dose compounded vials should be used within 28 days after first puncture.
No dose adjustment vs IV: bioavailability ~100% (same as IV)
Gluteal or deltoid muscle; 23-25g needle, 1.0-1.5 inch depth. Well tolerated at 500 mg/mL in 1-2 mL volumes. Warm solution to room temperature; inject slowly over 30-60 seconds. Gold-standard route for wellness injectable carnitine.
Bioavailability similar to IM (~100%); tmax slightly prolonged
The hypertonic, mildly acidic solution creates an osmotic gradient at SC sites, drawing fluid and causing swelling and inflammatory nodules. At 500 mg/mL: hard, burning nodules documented lasting 4-5 months (T-Nation, AnabolicMinds forum threads). At 200 mg/mL: substantially better tolerated but still inferior to IM. Avoid SC unless IM is absolutely contraindicated.
Clinical deficiency: 50 mg/kg/day IV (≈3,500 mg/day for 70 kg adult). Push slowly over 2-3 minutes.
Not practical for home use. Required for severe deficiency states and hemodialysis patients. Anaphylaxis risk (laryngeal edema, bronchospasm) is highest with IV administration: epinephrine must be available in clinical settings (explicit FDA label warning).
Requires 3-6× higher dose (2,000-3,000 mg/day) to achieve comparable plasma levels; intestinal transporters saturate above 2 g; absorption decreases further at higher doses
Oral bioavailability 15-18% at supplement doses. GI side effects (nausea, diarrhea, abdominal cramps) more common than injectable. Significant TMAO production from gut bacterial conversion of carnitine → TMA → TMAO, not an issue with injectable route. Some clinic protocols use oral carnitine as maintenance after completing an injectable cycle.
Most common GLP-1 + carnitine clinic combination. L-carnitine supports fatty acid oxidation during GLP-1-induced caloric restriction and may help preserve lean mass during rapid weight loss.
250-500 mg L-carnitine IM 3×/week alongside weekly semaglutide injection
Same rationale as semaglutide stack. Compounded "CarniTide" (tirzepatide + L-carnitine single-vial formulation) is offered by some telehealth clinics.
250-500 mg L-carnitine IM 3×/week concurrent with tirzepatide
Synergistic mitochondrial support: NAD+ fuels the TCA cycle and beta-oxidation co-enzymes; L-carnitine handles fatty acid transport into the mitochondria. Core of the community "Mito Stack."
AMPK activator + fatty acid transport synergy. Part of the "Mito Stack" (MOTS-c + L-carnitine + NAD+ ± SS-31) used for metabolic and mitochondrial optimization.
L-carnitine inhibits thyroid hormone entry into cell nuclei at the nuclear receptor level, reducing thyroid hormone effectiveness. Clinically confirmed pharmacodynamic interaction. Monitor thyroid panel and adjust thyroid medication dose if needed.
L-carnitine may potentiate anticoagulant effect; case reports of increased bleeding risk documented. INR can rise unexpectedly: monitor closely when initiating or discontinuing L-carnitine in anticoagulated patients.
Pricing updated 2026-04-09
Seizures top the safety concern list. The FDA label for Carnitor carries a specific warning about seizure exacerbation in patients with or without pre-existing seizure disorders. Reports are rare, but this is a black-letter label warning that deserves attention before starting. Anaphylaxis is the other serious risk. The FDA prescribing information documents laryngeal edema and bronchospasm, particularly with intravenous administration. Clinical settings administering IV levocarnitine are required to have epinephrine available. For IM self-administration, true anaphylaxis is extremely uncommon, but anyone with known hypersensitivity to levocarnitine should not use it. Injection site reactions are the most common day-to-day complaint. Subcutaneous injection at 500 mg/mL causes hard, burning nodules that community users have documented lasting 4 to 5 months. Forum threads on T-Nation and AnabolicMinds describe these in detail. The solution is hypertonic and mildly acidic; SC tissue lacks the blood supply to absorb it quickly. Intramuscular injection is far better tolerated. Warm the vial to room temperature and inject slowly over 30 to 60 seconds to reduce the burning sensation. Fishy body odor affects a meaningful percentage of users. Trimethylamine (TMA), a metabolite of carnitine, gets excreted through sweat, breath, and urine. This is primarily an oral supplementation issue because gut bacteria drive the carnitine-to-TMA conversion. Injectable delivery largely bypasses that pathway. If you're using both oral and injectable, the oral component is likely the culprit. TMAO (trimethylamine N-oxide) production is the longer-term cardiovascular concern. Raised TMAO levels have been associated with increased cardiovascular risk in observational studies. Again, this is primarily a gut microbiome phenomenon relevant to oral dosing. Injectable carnitine sidesteps most TMAO production. GI symptoms (nausea, vomiting, diarrhea, abdominal cramps) occur more often with oral dosing but can still appear with injections. At doses above 3 grams per day, GI side effects become substantially more likely. In hemodialysis patients receiving 3 g/day IV, clinically meaningful increases in platelet aggregation have been documented. At typical wellness doses of 500 to 1,000 mg/day, this is not clinically relevant. When to stop: persistent injection site nodules (reassess route and concentration), any seizure activity, signs of anaphylaxis (throat tightening, difficulty breathing, hives), or severe hypersensitivity reaction.
Verify L-Carnitine dosing and safety with a second opinion
L-carnitine (levocarnitine) is an FDA-approved drug with a USP monograph (brand Carnitor). Compounded versions from established 503A pharmacies (Empower Pharmacy, Kare Rx, Defy Medical) use pharmaceutical-grade active ingredient. Endogenous molecule with decades-long clinical safety record.
| Test | When | Target |
|---|---|---|
| Serum free carnitine | Baseline and 8-12 weeks (required for clinical deficiency use); optional for wellness use | 20-50 µmol/L (free carnitine, plasma) |
| Thyroid function panel (TSH, free T3, free T4) | Baseline then 6-8 weeks after initiating L-carnitine: only if on concurrent thyroid medication (levothyroxine, liothyronine) | — |
| INR / prothrombin time | Within 1-2 weeks of initiating L-carnitine if patient is on warfarin or acenocoumarol | — |
| Serum creatinine / eGFR | Baseline if renal impairment is present or suspected; quarterly ongoing | — |
Confirms genuine deficiency state and guides dose adequacy; determines whether supplementation will produce a meaningful effect
L-carnitine inhibits thyroid hormone nuclear receptor entry; may reduce thyroid hormone cellular effectiveness and require medication dose adjustment
L-carnitine may potentiate anticoagulant effect; INR can rise unexpectedly with concurrent use
Renal impairment reduces clearance of TMA and TMAO metabolites; dose reduction may be required in CKD to prevent toxic metabolite accumulation (FDA label warning)
Plasma carnitine levels rise immediately with injectable dosing. Some users report increased energy and warmth within hours of first injection.
Tissue carnitine stores begin to replenish. Mild improvements in exercise tolerance and recovery may be noticed.
Fat oxidation during exercise measurably increases. Body composition changes begin to appear when combined with caloric deficit and training.
Full metabolic adaptation. Meta-analysis data suggests average 1.2 kg weight reduction with continued use. Most pronounced in overweight individuals with consistent exercise.
Days 1 to 3: Plasma carnitine levels climb within 1 to 2 hours of an IM injection. No body composition change happens this fast. Many users notice a bump in energy and a warm sensation within hours of their first shot; some report sharper focus and better motivation to train. Weeks 1 to 2: Skeletal muscle carnitine stores start refilling. Acetylcarnitine availability rises, improving how flexibly your cells switch between fuel sources. Expect mild improvements in exercise tolerance and reduced post-workout soreness. Injection site reactions, if any, typically resolve by end of week one. If you injected subcutaneously at 500 mg/mL, hard nodules may form. Switch to intramuscular immediately. Weeks 3 to 6: Fatty acid flux through CPT-I increases during exercise. Body composition changes become visible when paired with a caloric deficit. Users report increased vascularity, better pump during training, and consistent energy above baseline. Fishy odor may surface if you're also taking oral carnitine. Weeks 7 to 12: Full metabolic adaptation territory. The RCT data [1] points to 1.21 kg mean weight reduction vs placebo at matched bioavailable oral doses. The umbrella meta-analysis (n=16,352) confirmed 1.34 cm waist circumference reduction. Effects are more pronounced in overweight individuals and those with type 2 diabetes or metabolic dysfunction. Energy improvement is the most consistent benefit reported by the community. Users universally describe L-Carnitine as a "modifier" where results depend on diet and training discipline.
Plasma carnitine rises within 1-2 hours of IM injection (tmax ~1-2h) or immediately with IV. No body composition change at this stage.
Many users notice increased energy and warmth within hours of first injection. Some report improved focus and exercise motivation.
Skeletal muscle carnitine stores begin to increase. Acetylcarnitine availability rises, improving metabolic flexibility. PMID 40019115 documents skeletal muscle acetylcarnitine +31% at rest (p=0.008) after 12 weeks oral: early tissue saturation occurs here.
Improved exercise tolerance and reduced post-workout soreness (DOMS). Some report improved pump during training sessions.
CPT-1 activity and fatty acid flux into mitochondria increase during exercise. Meaningful performance and metabolic benefit in deficient individuals; more modest in replete.
Body composition changes become noticeable with concurrent caloric deficit. Increased vascularity and pump. Energy levels consistently elevated vs baseline.
RCT endpoint: mean body weight -1.21 kg vs placebo (oral 2,000 mg/day, PMID 32359762). Waist circumference -1.34 cm (umbrella meta-analysis, n=16,352). More pronounced effect in overweight/obese individuals and those with T2D or metabolic dysfunction.
Sustained fat loss support with continued caloric deficit. Energy benefit is the most consistent reported outcome. Users universally describe carnitine as a "modifier": results depend on diet/training discipline.
Source: FDA Prescribing Information (Carnitor Injection), Clinical Pharmacology section: mean apparent terminal elimination half-life
Loading the interactive decay curve.
L-Carnitine as levocarnitine injection (brand Carnitor, manufactured by American Regent) is FDA-approved with a New Drug Application (NDA 020182). The approved indication is treatment of primary and secondary carnitine deficiency. A valid prescription is required. Compounded injectable L-Carnitine (typically 500 mg/mL) is available from licensed 503A compounding pharmacies. These require an individual patient prescription. Empower Pharmacy, Kare Rx, and Defy Medical are among the most commonly referenced suppliers. Compounded versions are not FDA-approved but are legally dispensed under Section 503A of the Federal Food, Drug, and Cosmetic Act. Oral L-Carnitine (acetyl-L-carnitine, L-carnitine L-tartrate) is sold as a dietary supplement and does not require a prescription. Do not confuse oral supplement forms with injectable levocarnitine, as they have different pharmacokinetics and are regulated differently. L-Carnitine is not a WADA-banned substance and is permitted in competitive athletics. This content is for research and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any injectable medication.
Peptide Schedule Research TeamReviewed Apr 202611 Citations
